Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection.

Annals of Hepatology（2016）

引用 1|浏览38

暂无评分

摘要

Background. Patient race and ethnicity have historically impacted HCV treatment response. This phase 3 study evaluated daclatasvir with peginterferon-alfa-2a/ribavirin (pegIFN alfa-2a/RBV) in treatment-naive black/African American (AA), Latino, and white non-Latino patients with chronic HCV genotype 1 infection.

查看译文

关键词

NS5A Inhibitor,Antiviral therapy,Liver disease,Ethnicity,Race

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要